Wednesday, December 11, 2024 6:42:24 PM
There is only one simple answer: time & increase of approval in several countries.
Stock split 1-10 Open High Low Close
Low 10/19/1998 $15.00 $15.00 $12.50 $12.50
High 11/19/2001 $268.50 $281.00 $265.10 $279.70
1/10 stock split actual value$26.85 $28.10 $26.51 $27.97
Profit $15.47
123.76%
So if you take $0.46 X 123% =$1.0293 after 3 years , that was the best they could do in 1998 after 3 years + 1 month
Please correct me if I am wrong or if my math has flaws.
A buyback right now makes no sense , because there is no volume and it would take for ever
for AMRN to get the $50 million Completion. When the stock is above $1.00 and the volume goes back to $5 to & million daily
as it was last year in November and this year in march ( some days), then should startt to buyback.
Only the nickel & dime approach as some say will work. Once we reach a dollar the delisting goes away
and hopefully additional sales come in from newly approved countries. I do not believe that institutions will
wait until the price is $5 to buy into the company. Once they see substantial additional sales realized (I see the 13 F filings for
the 3rd & 4th Quarter and some of the institutions are buying shares at $068, $0.90, Kynam Investments, BNP Paribas, etc.
just to name a few.
Your comments are appreciated.
Stock split 1-10 Open High Low Close
Low 10/19/1998 $15.00 $15.00 $12.50 $12.50
High 11/19/2001 $268.50 $281.00 $265.10 $279.70
1/10 stock split actual value$26.85 $28.10 $26.51 $27.97
Profit $15.47
123.76%
So if you take $0.46 X 123% =$1.0293 after 3 years , that was the best they could do in 1998 after 3 years + 1 month
Please correct me if I am wrong or if my math has flaws.
A buyback right now makes no sense , because there is no volume and it would take for ever
for AMRN to get the $50 million Completion. When the stock is above $1.00 and the volume goes back to $5 to & million daily
as it was last year in November and this year in march ( some days), then should startt to buyback.
Only the nickel & dime approach as some say will work. Once we reach a dollar the delisting goes away
and hopefully additional sales come in from newly approved countries. I do not believe that institutions will
wait until the price is $5 to buy into the company. Once they see substantial additional sales realized (I see the 13 F filings for
the 3rd & 4th Quarter and some of the institutions are buying shares at $068, $0.90, Kynam Investments, BNP Paribas, etc.
just to name a few.
Your comments are appreciated.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
